Illumina
 Illumina    | |
|---|---|
Illumina, Inc. is an American company. Incorporated in April 1998, Illumina develops, manufactures, and markets integrated systems for the analysis of genetic variation and biological function. The company provides a line of products and services that serves the sequencing, genotyping and gene expression, and proteomics markets. Its headquarters are located in San Diego, California.
Illumina's technology had purportedly by 2014 reduced the cost of DNA sequencing a human genome to US$1,000, down from a price of $1 million in 2007.[1] Customers include genomic research centres, pharmaceutical companies, academic institutions, clinical research organisations, and biotechnology companies.
In May 2020, a new partnership to sequence human genomes in the fight against COVID-19 was announced: Genomics England, is partnering with the GenOMICC consortium, Illumina and the NHS to launch the research drive, which will reach patients in 170 intensive care units (ICUs) throughout the UK. The project is backed by £28 million from Genomics England, UK Research and Innovation, the Department of Health and Social Care and the National Institute for Health Research. Illumina will sequence all 35,000 genomes and share some of the cost via an in-kind contribution. Whole genome sequencing will be carried out by Illumina at its laboratories in Cambridge, UK, where they successfully delivered the 100,000 Genomes Project together with Genomics England and the NHS.
Paula Dowdy, General Manager and SVP Illumina, EMEA, said:
- “We have a long-standing partnership with Genomics England and are proud to support this new genomics initiative from our Cambridge-based lab. The results will establish a unique platform for researchers to understand the human response to coronavirus infection, leading towards new treatments and ways to control infection spread.”[2]
References
This page imported content from Wikipedia on 14 May 2020.Wikipedia is not affiliated with Wikispooks. Original page source here
